Peptides

Orano Med, a biotechnology company developing Lead-212 (212Pb) targeted alpha therapy against cancer, and Orbit Discovery, a company discovering therapeutic peptide hits, have entered into a collaboration to discover specific peptide receptor radionuclide therapies (PRRT) against cancer cells and advance the development of novel radiopharmaceuticals.   Under the terms of the agreement, Orbit will deploy […]

HBC Immunology (a subsidiary of Hofseth BioCare) has secured seed capital financing of approximately $900,000 from external investors to commence preclinical animal trials with its patented peptides, FT-002 and FT-005. These are analogues of peptides discovered by HBC in ProGo bioactive peptides, which modulate iron metabolism and have Qualified Health claims granted for this mode […]

Italian contract research organisation IRBM has signed a new agreement with Merck & Co Inc (MSD outside the USA and Canada) to continue their collaboration in the peptide therapeutics area. “The success of this collaboration is reflected by the outstanding achievements in the delivery of orally available peptide candidates,” said Elisabetta Bianchi, Senior Director of […]

Bayer and Bicycle Therapeutics have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialise Bicycle radioconjugates for multiple oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured and bind to targets with high affinity and selectivity, affording high tumour penetration and fast excretion from healthy […]

Companies Evergreen Discovery and Orbit Discovery have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals. The agreement covers activities including designing peptide libraries, hit identification and hit validation to confirm cell surface binding properties. The radiopharmaceuticals market is rapidly expanding with the development of a variety […]

Orbit Discovery and start-up SanegeneBio have entered into a Master Service Agreement to identify tissue-specific delivery of a wide range of RNA therapeutics.  The agreement covers activities ranging from hit ID to cell-based internalisation studies, with an option for Sanegene to further develop the hits resulting from the screening activities.  Orbit’s technology enables the screening […]

Biosynth are experts in complex chemistry, peptides and key biological raw materials, providing more than half a million research products plus end-to-end manufacturing including discovery, optimisation, and scale up. Biosynth manufacture and source a vast range of chemical and biochemical products and provide a full range of products and services to support life science research […]

Using deadly spider venom to treat heart attacks is one of many new discoveries currently being developed at a national research centre headquartered at The University of Queensland. The Australian Research Council (ARC) Centre of Excellence for Innovations in Peptide and Protein Science (CIPPS) was launched this week at its UQ headquarters. Researchers have found […]